Literature DB >> 11156866

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

M Guérin1, W Le Goff , T S Lassel, A Van Tol , G Steiner, M J Chapman.   

Abstract

Plasma cholesteryl ester transfer protein (CETP) facilitates intravascular lipoprotein remodeling by promoting the heteroexchange of neutral lipids. To determine whether the degree of triglyceridemia may influence the CETP-mediated redistribution of HDL CE between atherogenic plasma lipoprotein particles in type 2 diabetes, we evaluated CE mass transfer from HDL to apoB-containing lipoprotein acceptors in the plasma of type 2 diabetes subjects (n=38). In parallel, we investigated the potential relationship between CE transfer and the appearance of an atherogenic dense LDL profile. The diabetic population was divided into 3 subgroups according to fasting plasma triglyceride (TG) levels: group 1 (G1), TG<100 mg/dL; group 2 (G2), 100<TG<200 mg/dL; and group 3 (G3), TG>200 mg/dL. Type 2 diabetes patients displayed an asymmetrical LDL profile in which the dense LDL subfractions predominated. Plasma levels of dense LDL subfractions were strongly positively correlated with those of plasma triglyceride (TG) (r=0.471; P:=0.0003). The rate of CE mass transfer from HDL to apoB-containing lipoproteins was significantly enhanced in G3 compared with G2 or G1 (46.2+/-8.1, 33.6+/-5.3, and 28.2+/-2.7 microg CE transferred. h(-1). mL(-1) in G3, G2, and G1, respectively; P:<0.0001 G3 versus G1, P:=0.0001 G2 versus G1, and P:=0.02 G2 versus G3). The relative capacities of VLDL and LDL to act as acceptors of CE from HDL were distinct between type 2 diabetes subgroups. LDL particles represented the preferential CE acceptor in G1 and accounted for 74% of total CE transferred from HDL. By contrast, in G2 and G3, TG-rich lipoprotein subfractions accounted for 47% and 72% of total CE transferred from HDL, respectively. Moreover, the relative proportion of CE transferred from HDL to VLDL(1) in type 2 diabetes patients increased progressively with increase in plasma TG levels. The VLDL(1) subfraction accounted for 34%, 43%, and 52% of total CE transferred from HDL to TG-rich lipoproteins in patients from G1, G2, and G3, respectively. Finally, dense LDL acquired an average of 45% of total CE transferred from HDL to LDL in type 2 diabetes patients. In conclusion, CETP contributes significantly to the formation of small dense LDL particles in type 2 diabetes by a preferential CE transfer from HDL to small dense LDL, as well as through an indirect mechanism involving an enhanced CE transfer from HDL to VLDL(1), the specific precursors of small dense LDL particles in plasma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156866     DOI: 10.1161/01.atv.21.2.282

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

1.  Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism.

Authors:  Yan Liu; Richard E Morton
Journal:  Curr Opin Lipidol       Date:  2020-08       Impact factor: 4.776

Review 2.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

3.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

4.  Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Authors:  Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles Fruchart; Marja-Riitta Taskinen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

5.  Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.

Authors:  Maurizio Bevilacqua; Barbara Guazzini; Velella Righini; Massimo Barrella; Rosanna Toscano; Enrica Chebat
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

6.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

7.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia.

Authors:  Katherine K Anagnostopoulou; Genovefa D Kolovou; Peggy M Kostakou; Constantinos Mihas; Georgios Hatzigeorgiou; Christina Marvaki; Dimitrios Degiannis; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Lipids Health Dis       Date:  2009-06-26       Impact factor: 3.876

Review 10.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.